Martel Sylvain
NanoRobotics Laboratory, Department of Computer and Software Engineering, and the Institute of Biomedical Engineering, École Polytechnique de Montréal (EPM), (Québec), P.O. Box 6079 Station Centre-ville, H3C 3A7 Canada.
Annu Int Conf IEEE Eng Med Biol Soc. 2010;2010:1942-5. doi: 10.1109/IEMBS.2010.5627768.
Magnetic Resonance Targeting (MRT) uses MRI for gathering tracking data to determine the position of microscale entities with the goal of guiding them towards a specific target in the body accessible through the vascular network. At full capabilities, a MRT platform designed to treat a human would consist of a clinical MRI scanner running special algorithms and upgraded to provide propulsion gradient up to approximately 400mT/m to enable entities as small as a few tens of micrometers in diameter and containing magnetic nanoparticles (MNP) to be steered at vessel bifurcations based on tracking information. Indeed, using a clinical MRI system, we showed that such single entity with a diameter as small as 15microm is detectable in gradient-echo scans. Among many potential interventions, targeted cancer therapy is a good initial application for such new microrobotic approach since secondary toxicity for the patient could be reduced while increasing therapeutic efficacy using lower dosages. Although many types of such entities are needed to provide a larger set of tools, here, only three initial types designed with different functionalities and for different types of cancer are briefly described. Initially designed for targeted chemo-embolization of liver tumors, the first type known as Therapeutic Magnetic Micro-Carriers (TMMC) consists in its present form of approximately 50 microm PLGA microparticles containing therapeutics and approximately 180 nm FeCo MNP. For the second type, MNP are not only used for propulsion and tracking, but also actuation based on a local elevation of the temperature. In its simplest form, it consists of approxiamtely 20 nm MNP embedded in a thermo-sensitive hydrogel known as PNIPA, allowing additional functionalities such as computer triggered drug release and targeted hyperthermia. The third type initially considered to target colorectal tumors, consists of 1-2 microm MR-trackable and controllable MC-1 Magnetotactic Bacteria (MTB) with propelling thrust force provided by two flagella bundles per cell exceeding 4 pN.
磁共振靶向(MRT)利用磁共振成像(MRI)收集跟踪数据,以确定微观实体的位置,目的是将它们引导至体内可通过血管网络到达的特定目标。在具备全部功能的情况下,一个旨在治疗人类的MRT平台将由一台运行特殊算法的临床MRI扫描仪组成,并进行升级以提供高达约400mT/m的推进梯度,从而使直径小至几十微米且含有磁性纳米颗粒(MNP)的实体能够根据跟踪信息在血管分叉处被引导。事实上,使用临床MRI系统,我们表明在梯度回波扫描中可以检测到直径小至15微米的单个此类实体。在众多潜在干预措施中,靶向癌症治疗是这种新型微型机器人方法的一个很好的初始应用,因为可以降低对患者的二次毒性,同时使用较低剂量提高治疗效果。尽管需要许多类型的此类实体来提供更广泛的工具集,但在此仅简要描述最初设计用于不同功能和不同类型癌症的三种初始类型。第一种类型称为治疗性磁性微载体(TMMC),最初设计用于肝脏肿瘤的靶向化疗栓塞,其目前的形式是约50微米的聚乳酸-羟基乙酸共聚物(PLGA)微粒,含有治疗药物和约180纳米的铁钴MNP。对于第二种类型,MNP不仅用于推进和跟踪,还基于局部温度升高进行驱动。其最简单的形式是约20纳米的MNP嵌入一种称为聚N-异丙基丙烯酰胺(PNIPA)的热敏水凝胶中,允许实现诸如计算机触发药物释放和靶向热疗等附加功能。第三种类型最初被认为用于靶向结直肠癌肿瘤,由1 - 2微米的可磁共振跟踪和可控的MC - 1趋磁细菌(MTB)组成,每个细胞的两个鞭毛束提供超过4皮牛的推进推力。